Drug Profile
DA 9805
Alternative Names: DA-9805 - Dong A STLatest Information Update: 09 Dec 2022
Price :
$50
*
At a glance
- Originator Dong-A ST
- Class Antiparkinsonians; Herbal medicines; Neuroprotectants
- Mechanism of Action Antioxidants; Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 08 Dec 2022 DA 9805 is still in phase IIa development in Parkinson's disease (Newly diagnosed) in USA (unspecified route) (Dong-A ST pipeline, December 2022)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in South Korea
- 10 Apr 2019 Dong-A ST completes a phase II clinical trial in Parkinson's disease (Newly diagnosed) in USA (unspecified route) (NCT03189563)